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Stem Cell Research (2015) 14, 132New Editor-in-ChiefI am very excited to accept the appointment as
Editor-in-Chief of Stem Cell Research (SCR). Over the last
several years, SCR has established itself as a major
chronicler of developments in the stem cell field, and as an
important member of the larger Elsevier family. Andrew
Elefanty, Monash Immunology and Stem Cell Lab, Monash
University, the Editor-in-Chief of SCR since 2007, has lead
the journal in establishing high standards and vital coverage.
Andrew not only inaugurated SCR, but accomplished the
nearly impossible — that is, to attract many high-quality
papers at a time when stem cell journal competition was
intense. I look forward to working with the deputy editor,
Pam Robey, National Institutes of Health, National Institute
of Dental and Craniofacial Research (NIDCR), the associate
editors (P. Bianco, P. Gadue, M. Grompe and K. Orwig), and
the editorial board, to maintain and build upon the strong
foundations at SCR.
This is an incredibly exciting and challenging time in stem
cell research, as it dovetails with and invigorates the field
of regenerative medicine. We are on the cusp of major
milestones in basic discoveries and clinical applications.
Recent efforts to map the “epigenome” of stem cells and the
exploration of how transcription factors influence cell fate
have revealed the most fundamental structural underpin-
nings of stem cells, and shed light on cell functions in
general. In the next three to five years, we can expect a
revolution in our understanding of the inner workings of the
networks and pathways that enable cells to remain stable
and responsive.
We have also seen the advent of technologies like cellular
programming and reprogramming, gene editing, advanced
biophysical tools, imaging and optogenetics. This knowledge
gained on the cellular level will have an inevitable impact
on the understanding and treatment of such devastating
maladies as Parkinson's disease, heart disease, cancer and
diabetes. There is also the promise of important break-
throughs in the clinic, as trials have been initiated utilizing
both pluripotent stem-cell-derived products and adult cell
products. The results of these studies will not only accelerate
the development of treatments and augment related clinical
disciplines like gene therapy; they will also provide fertilehttp://dx.doi.org/10.1016/j.scr.2014.12.004
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(http://creativecommons.org/licenses/by/4.0/).ground for new basic insights into cell function and cell
pathology.
I see SCR at the center of these micro- and macro-
developments, by promoting coverage of basic scientific
research and fast-tracked studies on specific diseases. I
believe that SCR will become a must-read for researchers
and clinicians — not just in cellular biology but in re-
generative medicine, oncology, cardiology and neurology.
This journal can help knit the medical and research
communities together by publishing reviews and original
articles on basic and applied research, on methods and
processes, and on news and current thinking, that can be
utilized by both the practicing clinician and the cell biologist.
Why shouldn't the neurologist be familiar with Oct4, Sox2,
Klf4 and cMyc, and, conversely, the epigenomologist under-
stand GMP?
Robert Heinlein once said that “specialization is for
insects” — perhaps the division between M.D.'s and Ph.D.'s
belongs to the last century. SCR can be the journal that will
spark connections among seemingly divergent areas of
study, and encourage the disruptive and creative process
that is scientific research — after all, medicine is biology.
True discovery is impossible to predict, but research on
every stem cell, every molecule and every phenotype carries
great potential to reveal the secrets of embryonic develop-
ment and new ways to battle disease. In my opinion, the
“Copernican Revolution” is still in its infancy, and while
we all understand its blueprint, the details still need to
precipitate.
Quality and thorough review will remain the primary
criteria for the selection of articles, as SCR welcomes reports
on novel research, methodologies, hypotheses, observations
and models, in recognition of the broad relevance stem cell
science has to so many medical disciplines and fields.
I look forward to serving the editorial board of Stem Cell
Research and its community of readers.
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